Innovus Pharmaceuticals (Innovus Pharmaceuticals) EPS (Basic) : $-3.27 (TTM As of Sep. 2019)

View and export this data going back to 2008. Start your Free Trial

What is Innovus Pharmaceuticals EPS (Basic)?

Innovus Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Sep. 2019 was $-0.81. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2019 was $-3.27.

Innovus Pharmaceuticals's EPS (Diluted) for the three months ended in Sep. 2019 was $-0.81. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 was $-3.27.

Innovus Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2019 was $-0.81. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2019 was -3.27.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Innovus Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Innovus Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovus Pharmaceuticals EPS (Basic) Chart

Innovus Pharmaceuticals Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

EPS (Basic)

Get a 7-Day Free Trial

-21.00

-8.40

-15.75

-4.32

-4.16

Innovus Pharmaceuticals Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
EPS (Basic)	Get a 7-Day Free Trial															-1.20	-0.99	-0.81	-0.66	-0.81

Innovus Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Innovus Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2018 is calculated as

Basic EPS (A: Dec. 2018 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-8.279	-	0)	/	1.989
	=	-4.16

Innovus Pharmaceuticals's Basic EPS for the quarter that ended in Sep. 2019 is calculated as

Basic EPS (Q: Sep. 2019 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.236	-	0)	/	2.760
	=	-0.81

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.27

Innovus Pharmaceuticals (OTCPK:INNV) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Innovus Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Innovus Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovus Pharmaceuticals (Innovus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Innovus Pharmaceuticals Inc (OTCPK:INNV) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

8845 Rehco Road, San Diego, CA, USA, 92121

Website

http://www.innovuspharma.com

Innovus Pharmaceuticals Inc is engaged in the healthcare industry. It is a specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus distributes OTC medicines and consumer and health products directly, through commercial partners to primary care physicians, urologists, gynecologists and therapists, and directly to consumers through its on-line channels, retailers, and wholesalers.

Executives

Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Vivian H Liu	director
Henry Jemil Esber	director	38 ANGELL BROOK DRIVE, WEST BOYLSTON MA 01853
Randy Berholtz	officer: EVP, CORPORATE DEVELOPMENT	6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Ryan J Selhorn	officer: VP, CFO	4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Bassam Damaj	director, officer: CHIEF EXECUTIVE OFFICER	C/O BIO-QUANT, INC., 6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Robert Hoffman	officer: Chief Financial Officer	ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121
Morgan R Brown	officer: See remarks	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Jacki Bartholomew	director	175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Thomas L Harkness	director, officer: Secretary	175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Wallace Boyack	director, 10 percent owner, officer: President & CEO	175 S MAIN ST, NO 1212, SALT LAKE CITY UT 84111